Frequently Asked Questions
Nanotherapeutics
Nanotherapeutics are advanced medical treatments that use nanoscale particles, typically less than 100 nanometers in size, to deliver therapeutic compounds directly to targeted cells or tissues. This precision allows for enhanced effectiveness with reduced side effects compared to traditional treatments.
Traditional therapies circulate systemically, often affecting both healthy and diseased cells. Nanotherapeutics are engineered to seek out and bind to specific biological targets, such as cancer cells or inflamed tissue, allowing for controlled release and higher local concentrations of treatment where it matters most.
Nanotherapeutics are used in areas such as oncology (targeted cancer therapy), regenerative medicine, autoimmune modulation, neuroprotection, and anti-aging.
We primarily use biocompatible and biodegradable materials such as liposomes, polymeric nanoparticles, and exosome-like lipid vesicles. These materials are designed to safely degrade after delivering their therapeutic payload.
Nanoparticles can be surface-modified with targeting ligands, such as antibodies, peptides, or aptamers, that recognize receptors on specific cell types. This ensures the treatment localizes precisely where it is needed.
We can pair Wharton’s Jelly derived mesenchymal stem cell (WJ-MSC) exosomes or secretomes with nanoparticle systems to amplify regenerative and immunomodulatory effects.
All nanoparticles used in our protocols are formulated from materials with established safety profiles.
Diagnostics & Personalization
A liquid biopsy analyzes circulating tumor cells, DNA, and exosomes in your blood. This allows us to identify molecular targets and design nanoparticle formulations that engage those pathways, enabling precision therapy without invasive tissue sampling.
Based on your liquid biopsy results, our physicians design a nanotherapeutic protocol that delivers personalized therapies directly into cancer cells, mimicking a “Trojan Horse” approach.
Treatment & Experience
Yes. In longevity and wellness programs, nanoparticles can deliver antioxidants, NAD+ precursors, peptides, and mitochondrial enhancers to slow cellular aging and promote optimal performance.
Most patients experience minimal side effects, typically mild fatigue or temporary inflammation at the treatment site. Because nanoparticles allow for precise targeting, systemic toxicity is significantly reduced compared to conventional drugs.
Treatments are usually administered intravenously or through targeted injections, depending on the protocol.
Many patients report increased energy, reduced inflammation, or improved biomarkers within weeks. In regenerative and oncology applications, measurable results may take longer and are tracked through follow-up testing.
Protocols are tailored to your goals and biological response, ranging from a single targeted infusion to a multi-session program over several months.
Cost, Access & Logistics
Pricing depends on formulation complexity, number of sessions, and diagnostic requirements. Personalized treatment plans with transparent pricing are provided after consultation.
Currently, personalized nanomedicine treatments are not covered by insurance, except through Samaritan Ministries and other Christian Share Ministries. Financing options are available.
Nanotherapeutic approaches aim to improve cellular function, resilience, and signaling efficiency by enhancing delivery and bioavailability of therapeutic compounds at the cellular and subcellular level. Longevity-focused care may support mitochondrial health, reduce inflammatory burden, improve nutrient utilization, and promote more efficient repair mechanisms.
Long-term human data on many nanotherapeutic modalities are still evolving. Evidence suggests that when appropriately formulated and dosed, many nano-delivery systems are well tolerated. Long-term outcomes depend on compound selection, delivery platform, dosing frequency, and patient biology. Ongoing monitoring and individualized risk assessment are essential.
Integration With Conventional Care
Nanotherapeutic protocols are designed for optimal efficacy based on individual test results, pathology reports, and current scientific evidence. While other therapies may be synergistic, interactions can be complex and highly individualized.
In many cases, yes, but only with careful coordination. Patients undergoing chemotherapy and/or radiation are evaluated on a case-by-case basis, with direct communication between the treating oncologist and our medical team.
Governance, Ethics & Expectations
This program is investigational and adjunctive and is not FDA-approved as a cancer treatment. Components may involve FDA-approved substances used in non-standard, research, or supportive contexts under physician oversight and informed consent.
Care is delivered under formal clinical governance, including physician oversight, informed consent, protocolized care pathways, and institutional review where applicable. Patients are advised to remain under the care of their primary physician and oncologist.
Risks vary by intervention and may include infusion-related, metabolic, or immune-modulating effects. Therapies with known direct tumor-stimulatory risk or established oncologic contraindications are excluded.
We encourage transparency, provide protocol summaries upon request, and defer all oncologic decision-making to the treating physician.
Patient Fit & Outcomes
Each individual is evaluated on a case-by-case basis.
Goals differ. Early-stage patients focus on recovery and resilience, while late-stage patients focus on symptom support and quality of life.
Participation is highest among solid tumors, including breast, colorectal, prostate, and gynecologic cancers. No cancer-specific efficacy is claimed.
Through informed consent, documented counseling, and repeated clarification that outcomes are uncertain and patient-specific.
Data, Outcomes & Accountability
Tumor response, safety events, laboratory trends, symptom scores, functional status, adherence, and patient-reported outcomes.
Monitoring commonly includes circulating tumor cell (CTC) bloodwork and quarterly imaging when appropriate.